NBIX — Neurocrine Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $12.88bn
- $11.40bn
- $2.86bn
Annual cashflow statement for Neurocrine Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 89.6 | 155 | 250 | 341 | 479 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 135 | 218 | 147 | 369 | 237 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 16.7 | -67.4 | 28.2 | -19.2 | -129 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 257 | 339 | 390 | 595 | 783 |
| Capital Expenditures | -23.4 | -16.5 | -28.3 | -38.2 | -34 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -107 | -161 | -439 | -88.6 | -230 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -130 | -177 | -467 | -127 | -264 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 27.4 | -234 | 65.3 | -487 | -38.3 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 154 | -73.3 | -11.6 | -18.1 | 480 |